' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

PACHMAYR JOHANNA
Universitätsinstitut für Pharmazie

Publikationen | Forscherprofil

38 Publikationen

2019

Beiträge in Fachzeitschriften

Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.
Ardelt, MA; Fröhlich, T; Martini, E; Müller, M; Kanitz, V; Atzberger, C; Cantonati, P; Meßner, M; Posselt, L; Lehr, T; Wojtyniak, JG; Ulrich, M; Arnold, GJ; König, L; Parazzoli, D; Zahler, S; Rothenfußer, S; Mayr, D; Gerbes, A; Scita, G; Vollmar, AM; Pachmayr, J;
Hepatology. 2019; 69(1):376-393
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Cdk5 Inhibition - The Key to Enhancing the Standard of Care in Hepatocellular Carcinoma Treatment.
Ardelt, MA; Fröhlich, T; Martini, E; Müller, M; Kanitz, V; Atzberger, C; Cantonati, P; Meßner, M; Posselt, L; Lehr, T; Wojtyniak, JG; Ulrich, M; Arnold, GJ; König, L; Parazzoli, D; Zahler, S; Rothenfußer, S; Mayr, D; Gerbes, A; Scita, G; Vollmar, AM; Pachmayr, J;
Final Programme & Book of Abstracts.. 2019; -26th Scientific Congress of the Austrian Pharmaceutical Society ; 25.-27.04.2019; Graz.
Abstracts (Zeitschrift)
Potential to improve the therapeutic situation of HCC patients - The influence of Regorafenib and Lenvatinib treatment in combination with Cdk5 inhibition in HCC.
Ardelt, MA; Huber-Cantonati, P; Pachmayr, J;
Final Programme & Book of Abstracts.. 2019; -26th Scientific Congress of the Austrian Pharmaceutical Society; 25.-27.04.2019; Graz.
Abstracts (Zeitschrift)
Potential to improve the therapeutic situation of HCC patients - The influence of Regorafenib and Lenvatinib treatment in combination with Cdk5 inhibition in HCC.
Ardelt, MA; Huber-Cantonati, P; Pachmayr, J;
10. Paracelsus Science Get Together Abstractband 2019. 2019; -10. Paracelsus Science Get Together ; 28.06.2019; Nürnberg.
Abstracts (Zeitschrift)
Diamonds in the rough - With low application Antibiotics against Tumor Relapse of sorafenib-resistant Hepatocellular Carcinoma.
Meßner, M; Zischka, H; Schmitt, S; Ardelt, MA; Huber-Cantonati, P; Fröhlich, T; Arnold, GJ; Atzberger, C; Müller, M; Pein, H; Koeberle, A; Zobel, LM; Koenig, L; Vollmair, AM; Pachmayr, J;
Final Programme & Book of Abstracts.. 2019; -26th Scientific Congress of the Austrian Pharmaceutical Society ; 25.-27.04.2019; Graz.
Abstracts (Zeitschrift)

2018

Beiträge in Fachzeitschriften

Design and synthesis of tailored human caseinolytic protease P inhibitors.
Gronauer, TF; Mandl, MM; Lakemeyer, M; Hackl, MW; Messner, M; Korotkov, VS; Pachmayr, J; Sieber, SA
CHEM COMMUN. 2018; 54(70): 9833-9836.
Originalarbeiten (Zeitschrift)
The novel brassinosteroid analog BR4848 inhibits angiogenesis in human endothelial cells and induces apoptosis in human cancer cells in vitro
Rarova, L; Sedlak, D; Oklestkova, J; Steigerova, J; Liebl, J; Zahler, S; Bartunek, P; Kolar, Z; Kohout, L; Kvasnica, M; Strnad, M
J STEROID BIOCHEM. 2018; 178: 263-271.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Inhibition of Cdk5 - Introducing New Strategies to Prevent Sorafenib Treatment Escape in HCC Cells.
Ardelt, MA; Fröhlich, T, Martini, E; Müller, M; Kanitz, V; Atzberger, C; Posselt, L; Lehr, T; Wojtyniak, JG; Ulrich, M; Arnold, GJ; König, L; Parazzoli, D; Zahler, S; Rothenfußer, S; Mayr, D; Gerbes, A; Scita, G; Vollmar, AM; Pachmayr, J;
Paracelsus Science Get Together Abstractband 2018.. 2018; 98-98.-Paracelsus Science Get Together 2018; 29.6.2018; Paracelsus Medizinische Privatuniversität Salzburg. (ISBN: 978-3-200-05737-1 )
Abstracts (Zeitschrift)
Epithelial-to-mesenchymal transition and evasive PI3K/Akt pathway activation contribute to Sorafenib-resistance of Hepatocellular Carcinoma.
Meßner, M; Ardelt, MA; Fröhlich, T; Arnold, GJ; Vollmar, AM; Pachmayr, J;
Paracelsus Science Get Together Abstractband 2018.. 2018; 175-175.-Paracelsus Science Get Together 2018; 29.6.2018; Paracelsus Medizinische Privatuniversität Salzburg. (ISBN: 978-3-200-05737-1 )
Abstracts (Zeitschrift)

2017

Beiträge in Fachzeitschriften

Inhibition of Cdk5 induces cell death of tumor-initiating cells.
Mandl, MM; Zhang, S; Ulrich, M; Schmoeckel, E; Mayr, D; Vollmar, AM; Liebl, J;
Br J Cancer. 2017; 116(7): 91-922.
Originalarbeiten (Zeitschrift)
Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT
Merk, H; Messer, P; Ardelt, MA; Lamb, DC; Zahler, S; Muller, R; Vollmar, AM; Pachmayr, J
MOL CANCER THER. 2017; 16(11): 2329-2339.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Cyclin-dependent Kinase 5 Inhibits Osteoblast Differentiation to Regulate Bone Integrity.
Ahmad, M; Vettorazzi, S; Vazquez, DC; Lai, D; Kroll, T; Vuijc-Spasic, M; Ploubidou, A; Pachmayr, J; Tuckermann, J
J BONE MINER RES. 2017; 32: S179-S179.
Abstracts (Zeitschrift)

2016

Beiträge in Fachzeitschriften

Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.
Herzog, J; Ehrlich, SM; Pfitzer, L; Liebl, J; Fröhlich, T; Arnold, GJ; Mikulits, W; Haider, C; Vollmar, AM; Zahler, S;
Oncotarget. 2016; 7(19): 27108-27121.
Originalarbeiten (Zeitschrift)
Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.
Merk, H; Zhang, S; Lehr, T; Müller, C; Ulrich, M; Bibb, JA; Adams, RH; Bracher, F; Zahler, S; Vollmar, AM; Liebl, J;
Oncotarget. 2016; 7(5): 6088-6104.
Originalarbeiten (Zeitschrift)
Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation
Unzue, A; Lafleur, K; Zhao, HT; Zhou, T; Dong, J; Kolb, P; Liebl, J; Zahler, S; Caflisch, A; Nevado, C
EUR J MED CHEM. 2016; 112: 347-366.
Übersichtsarbeiten

2015

Beiträge in Fachzeitschriften

Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.
Ehrlich, SM; Liebl, J; Ardelt, MA; Lehr, T; De Toni, EN; Mayr, D; Brandl, L; Kirchner, T; Zahler, S; Gerbes, AL; Vollmar, AM;
J Hepatol. 2015; 63(1):102-113
Originalarbeiten (Zeitschrift)
Cdk5 and Foxc2--a new relationship in the lymphatic vasculature.
Liebl, J;
Oncotarget. 2015; 6(26):21799-21801
Originalarbeiten (Zeitschrift)
Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2.
Liebl, J; Zhang, S; Moser, M; Agalarov, Y; Demir, CS; Hager, B; Bibb, JA; Adams, RH; Kiefer, F; Miura, N; Petrova, TV; Vollmar, AM; Zahler, S;
Nat Commun. 2015; 6:7274
Originalarbeiten (Zeitschrift)
Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.
Schneider, LS; von Schwarzenberg, K; Lehr, T; Ulrich, M; Kubisch-Dohmen, R; Liebl, J; Trauner, D; Menche, D; Vollmar, AM;
Cancer Res. 2015; 75(14):2863-2874
Originalarbeiten (Zeitschrift)
In vitro anti-cancer effects of the actin-binding natural compound rhizopodin.
Zhang, S; Menche, D; Zahler, S; Vollmar, AM; Liebl, J; Förster, F;
Pharmazie. 2015; 70(9):610-615
Originalarbeiten (Zeitschrift)
Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.
Zhang, S; Schneider, LS; Vick, B; Grunert, M; Jeremias, I; Menche, D; Müller, R; Vollmar, AM; Liebl, J;
Oncotarget. 2015; 6(41):4350-4328
Originalarbeiten (Zeitschrift)

2014

Beiträge in Fachzeitschriften

Pretubulysin: a new option for the treatment of metastatic cancer.
Braig, S; Wiedmann, RM; Liebl, J; Singer, M; Kubisch, R; Schreiner, L; Abhari, BA; Wagner, E; Kazmaier, U; Fulda, S; Vollmar, AM;
Cell Death Dis. 2014; 5: e1001
Originalarbeiten (Zeitschrift)
In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor.
Menhofer, MH; Bartel, D; Liebl, J; Kubisch, R; Busse, J; Wagner, E; Müller, R; Vollmar, AM; Zahler, S;
Cardiovasc Res. 2014; 104(2):303-314
Originalarbeiten (Zeitschrift)
Regulation of endothelial signaling and migration by v-ATPase.
Rath, S; Liebl, J; Fürst, R; Vollmar, AM; Zahler, S;
Angiogenesis. 2014; 17(3):587-601
Originalarbeiten (Zeitschrift)

2013

Beiträge in Fachzeitschriften

Indirubin derivative 6BIO suppresses metastasis.
Braig, S; Kressirer, CA; Liebl, J; Bischoff, F; Zahler, S; Meijer, L; Vollmar, AM;
Cancer Res. 2013; 73(19):6004-6012
Originalarbeiten (Zeitschrift)
Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.
Ivanov, KI; Agalarov, Y; Valmu, L; Samuilova, O; Liebl, J; Houhou, N; Maby-El Hajjami, H; Norrmén, C; Jaquet, M; Miura, N; Zangger, N; Ylä-Herttuala, S; Delorenzi, M; Petrova, TV;
Mol Cell Biol. 2013; 33(19):3749-3761
Originalarbeiten (Zeitschrift)
Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors.
Weitensteiner, SB; Liebl, J; Krystof, V; Havlíček, L; Gucký, T; Strnad, M; Fürst, R; Vollmar, AM; Zahler, S;
PLoS One. 2013; 8(1):e54607
Originalarbeiten (Zeitschrift)

2012

Beiträge in Fachzeitschriften

Brassinosteroids inhibit in vitro angiogenesis in human endothelial cells.
Rárová, L; Zahler, S; Liebl, J; Kryštof, V; Sedlák, D; Bartůněk, P; Kohout, L; Strnad, M;
Steroids. 2012; 77(13):1502-1509
Originalarbeiten (Zeitschrift)
Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives.
Rath, S; Liebl, J; Fürst, R; Ullrich, A; Burkhart, JL; Kazmaier, U; Herrmann, J; Müller, R; Günther, M; Schreiner, L; Wagner, E; Vollmar, AM; Zahler, S;
Br J Pharmacol. 2012; 167(5):1048-1061
Originalarbeiten (Zeitschrift)
IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors.
Regel, I; Eichenmüller, M; Joppien, S; Liebl, J; Häberle, B; Müller-Höcker, J; Vollmar, A; von Schweinitz, D; Kappler, R;
Mol Cancer. 2012; 11:9
Originalarbeiten (Zeitschrift)
The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1.
Wiedmann, RM; von Schwarzenberg, K; Palamidessi, A; Schreiner, L; Kubisch, R; Liebl, J; Schempp, C; Trauner, D; Vereb, G; Zahler, S; Wagner, E; Müller, R; Scita, G; Vollmar, AM;
Cancer Res. 2012; 72(22):5976-5987
Originalarbeiten (Zeitschrift)

2011

Beiträge in Fachzeitschriften

The selective P-TEFb inhibitor CAN508 targets angiogenesis.
Kryštof, V; Rárová, L; Liebl, J; Zahler, S; Jorda, R; Voller, J; Cankař, P;
Eur J Med Chem. 2011; 46(9):428-494
Originalarbeiten (Zeitschrift)
Twice switched at birth: cell cycle-independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells.
Liebl, J; Fürst, R; Vollmar, AM; Zahler, S;
Cell Signal. 2011; 23(11):1698-1707
Übersichtsarbeiten
Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl, J; Krystof, V; Vereb, G; Takács, L; Strnad, M; Pechan, P; Havlicek, L; Zatloukal, M; Fürst, R; Vollmar, AM; Zahler, S;
Angiogenesis. 2011; 14(3):28-91
Originalarbeiten (Zeitschrift)
Urokinase-type plasminogen activator promotes paracellular transmigration of neutrophils via Mac-1, but independently of urokinase-type plasminogen activator receptor.
Reichel, CA; Uhl, B; Lerchenberger, M; Puhr-Westerheide, D; Rehberg, M; Liebl, J; Khandoga, A; Schmalix, W; Zahler, S; Deindl, E; Lorenzl, S; Declerck, PJ; Kanse, S; Krombach, F;
Circulation. 2011; 124(17):1848-1859
Originalarbeiten (Zeitschrift)

2010

Beiträge in Fachzeitschriften

Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis.
Liebl, J; Weitensteiner, SB; Vereb, G; Takács, L; Fürst, R; Vollmar, AM; Zahler, S;
J Biol Chem. 2010; 285(46):35932-35943
Originalarbeiten (Zeitschrift)
Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro.
Zahler, S; Liebl, J; Fürst, R; Vollmar, AM;
Angiogenesis. 2010; 13(3):23-49
Originalarbeiten (Zeitschrift)

2009

Beiträge in Fachzeitschriften

Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases.
Koltermann, A; Liebl, J; Fürst, R; Ammer, H; Vollmar, AM; Zahler, S;
J Cell Mol Med. 2009; 13(8B):2122-2130
Originalarbeiten (Zeitschrift)